- Home
- JMSB vs MNPR Comparison
JMSB vs MNPR Comparison
Compare JMSB & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMSB
- MNPR
- Stock Information
- Founded
- JMSB 2005
- MNPR 2014
- Country
- JMSB United States
- MNPR United States
- Employees
- JMSB N/A
- MNPR N/A
- Industry
- JMSB Major Banks
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- JMSB Finance
- MNPR Health Care
- Exchange
- JMSB Nasdaq
- MNPR Nasdaq
- Market Cap
- JMSB 268.9M
- MNPR 249.5M
- IPO Year
- JMSB N/A
- MNPR 2019
- Fundamental
- Price
- JMSB $17.12
- MNPR $39.42
- Analyst Decision
- JMSB
- MNPR Strong Buy
- Analyst Count
- JMSB 0
- MNPR 5
- Target Price
- JMSB N/A
- MNPR $59.50
- AVG Volume (30 Days)
- JMSB 22.1K
- MNPR 17.8K
- Earning Date
- JMSB 04-23-2025
- MNPR 05-20-2025
- Dividend Yield
- JMSB 2.94%
- MNPR N/A
- EPS Growth
- JMSB 472.90
- MNPR N/A
- EPS
- JMSB 1.24
- MNPR N/A
- Revenue
- JMSB $54,782,000.00
- MNPR N/A
- Revenue This Year
- JMSB N/A
- MNPR N/A
- Revenue Next Year
- JMSB N/A
- MNPR N/A
- P/E Ratio
- JMSB $13.84
- MNPR N/A
- Revenue Growth
- JMSB 50.81
- MNPR N/A
- 52 Week Low
- JMSB $13.81
- MNPR $1.72
- 52 Week High
- JMSB $26.52
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- JMSB 59.33
- MNPR 49.46
- Support Level
- JMSB $16.67
- MNPR $37.81
- Resistance Level
- JMSB $17.83
- MNPR $44.40
- Average True Range (ATR)
- JMSB 0.57
- MNPR 3.61
- MACD
- JMSB 0.22
- MNPR -0.38
- Stochastic Oscillator
- JMSB 78.55
- MNPR 18.32
About JMSB John Marshall Bancorp Inc.
John Marshall Bancorp Inc provides banking services. The company offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.